Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -7M | -4M | -1M | -147K |
| Operating Income | -187M | -97M | -35M | -6M |
| EBITDA | -160M | -93M | -35M | -6M |
| Net Income | -168M | -98M | -41M | -6M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$4.47
+0.00% today
Window Change
+8.23%
Window
Jun 23, 2025 → Aug 20, 2025
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 42 bars · Jun 23, 2025 → Aug 20, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CARGO Therapeutics, Inc. Common Stock (CRGX) is a Healthcare stock with a market cap of $216.19M. The stock last traded around $4.47 and up 8.2% across the available one-year price window (Jun 23, 2025 → Aug 20, 2025). Baseline metrics include revenue growth of 0.0%, EPS growth of -56.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -56.3%, free cash flow -59.9% with operating margin -2445.2% and ROIC -80.4%. Valuation already assumes a fairly strong business story at price/sales 27.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CRGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CRGX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CRGX Max Drawdown
-3.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CRGX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$5.9M
+85.7% YoY
Free Cash Flow
-$5.4M
+83.4% YoY
Revenue Growth
+0.0%
EPS Growth
-56.3%
Gross Margin
-40.3%
Net Margin
-2297.2%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -7M | -4M | -1M | -147K |
| Operating Income | -187M | -97M | -35M | -6M |
| EBITDA | -160M | -93M | -35M | -6M |
| Net Income | -168M | -98M | -41M | -6M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 64M | 406M | 2M | 41K |
| Total Assets | 414M | 453M | 10M | 5M |
| Total Liabilities | 54M | 48M | 45M | 5M |
| Shareholder Equity | 360M | 405M | -35M | -175K |
| Total Debt | 29M | 29M | 25M | 3M |
| Net Debt | -35M | -377M | 23M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+83.0% YoY
Capital Expenditures
442K
+86.5% YoY
Free Cash Flow
5M
+83.4% YoY
Key ratios
Gross Margin
-40.3%
Operating Margin
-2445.2%
Net Margin
-2297.2%
ROE
-61.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.